Selexipag
FDA-approved product (tablet, oral), marketed as Selexipag, Uptravi.
- Registered studies
- 41
- Lab records
- 0
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Idiopathic and/or familial pulmonary arterial hypertension
- Idiopathic pulmonary arterial hypertension
- Pulmonary arterial hypertension
- Pulmonary hypertension
- Recurrent thrombophlebitis
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Platelet aggregation inhibitors excl. heparin
- FDA pharmacologic class
- Prostacyclin Receptor Agonist FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA45.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli27.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae16.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis59.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
41registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Selexipag with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- FurazolidoneExisting use: Other antiinfectives and antiseptics91.4% AI-predicted activityagainst M. tuberculosisLab records exist49 registered studies
- TriflupromazineExisting use: Psychosis90.6% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- ValdecoxibExisting use: Dysmenorrhea, Osteoarthritis, Rheumatic disease and 1 more88.6% AI-predicted activityagainst M. tuberculosisLab records exist31 registered studies
- CelecoxibExisting use: Ankylosing spondylitis, Cancer, Colorectal neoplasm and 15 more87.6% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Dorzolamide HydrochlorideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma86.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- MethazolamideExisting use: Glaucoma, Open-angle glaucoma85.6% AI-predicted activityagainst M. tuberculosisLab records exist11 registered studies
- AcetazolamideExisting use: Altitude sickness, Angle-closure glaucoma, Congestive heart failure and 5 more85.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Trifluoperazine HydrochlorideExisting use: Anxiety disorder, Mental or behavioural disorder, Psychosis and 1 more84.6% AI-predicted activityagainst M. tuberculosis1 registered study
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives84.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- NitrofurazoneExisting use: Eye infection, Leishmaniasis, Trypanosomiasis84.0% AI-predicted activityagainst M. tuberculosis8 registered studies
- BrinzolamideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma83.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- ZonisamideExisting use: Epilepsy, Focal-onset seizure, Partial epilepsy and 1 more82.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Withdrawal of Prostacyclin Pathway Therapy in Patients With Pulmonary Arterial Hypertension Receiving Sotatercept (WATERLOO)
NCT07700303 · start 2026-09-30
Registered record
- Registry ID
- NCT07700303
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Discontinuation of parenteral prostacyclins analogues or selexipag
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Not yet recruiting
- Start
- 2026-09-30
- Completion
- 2030-03-30
- Enrolment
- 78
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPulmonary Arterial HypertensionInterventionDiscontinuation of parenteral prostacyclins analogues or selexipagPhaseNot applicableRegistry statusNot yet recruitingA Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag
NCT07759804 · start 2026-09
Registered record
- Registry ID
- NCT07759804
- Conditions
- Pulmonary Arterial Hypertension (PAH)
- Interventions
- LIQ861 (treprostinil) inhalation powder
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Not yet recruiting
- Start
- 2026-09
- Completion
- 2027-06
- Enrolment
- 20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPulmonary Arterial Hypertension (PAH)InterventionLIQ861 (treprostinil) inhalation powderPhasePhase 4Registry statusNot yet recruitingRandomized Study of Triple Therapy vs Sildenafil Dose Optimization in Pulmonary Arterial Hypertension
NCT07713914 · start 2026-07-22
Registered record
- Registry ID
- NCT07713914
- Conditions
- Pulmonary Arterial Hypertension (PAH)
- Interventions
- Prostacyclin Pathway Agent; Sildenafil Dose Optimization
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Recruiting
- Start
- 2026-07-22
- Completion
- 2028-12-31
- Enrolment
- 196
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPulmonary Arterial Hypertension (PAH)InterventionProstacyclin Pathway Agent; Sildenafil Dose OptimizationPhasePhase 4Registry statusRecruitingBioequivalence Study to Compare Selexipag 400 Microgram Film Coated Tablets Versus Uptravi® (Selexipag) 400 Microgram Film Coated Tablets
NCT07694128 · start 2026-04-08
Registered record
- Registry ID
- NCT07694128
- Conditions
- Arterial Hypertension (PAH)
- Interventions
- Selexipag Film Coated Tablets (T1); Selexipag Film Coated Tablets (T2); Uptravi® (selexipag) film coated tablets
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2026-04-08
- Completion
- 2026-06-22
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionArterial Hypertension (PAH)InterventionSelexipag Film Coated Tablets (T1); Selexipag Film Coated Tablets (T2); Uptravi® (selexipag) film coated tabletsPhasePhase 1Registry statusCompletedPatient-Reported Outcomes and Adherence After Transition From Inhaled Iloprost to Oral Selexipag in Pulmonary Arterial Hypertension
NCT07356375 · start 2026-03-01
Registered record
- Registry ID
- NCT07356375
- Conditions
- Pulmonary Arterial Hypertension (PAH)
- Interventions
- Selexipag
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Not yet recruiting
- Start
- 2026-03-01
- Completion
- 2026-12-31
- Enrolment
- 32
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPulmonary Arterial Hypertension (PAH)InterventionSelexipagPhaseNot recordedRegistry statusNot yet recruitingLong-Term Outcomes of Selexipag in Schistosomiasis-Associated Pulmonary Arterial Hypertension
NCT07453030 · start 2026-03-01
Registered record
- Registry ID
- NCT07453030
- Conditions
- Pulmonary Arterial Hypertension (PAH)
- Interventions
- Not recorded
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Not yet recruiting
- Start
- 2026-03-01
- Completion
- 2027-03-01
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPulmonary Arterial Hypertension (PAH)InterventionNot recordedPhaseNot recordedRegistry statusNot yet recruitingBioequivalence Study to Compare Selexipag 400mcg Film Coated Tablets (400 mcg Selexipag) Versus Uptravi® 400mcg Film Coated Tablets (400 mcg Selexipag)
NCT06932198 · start 2025-01-09
Registered record
- Registry ID
- NCT06932198
- Conditions
- Pulmonary Arterial Hypertension (PAH)
- Interventions
- Selexipag Film Coated Tablets; Uptravi® Film Coated Tablets
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2025-01-09
- Completion
- 2025-03-25
- Enrolment
- 14
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPulmonary Arterial Hypertension (PAH)InterventionSelexipag Film Coated Tablets; Uptravi® Film Coated TabletsPhasePhase 1Registry statusCompletedEfficacy and Safety of Triple-targeted Drug Therapy in Treatment-naive Patients With Non-low-risk PAH: A Real-world, Multicenter Study
NCT06753981 · start 2024-12-10
Registered record
- Registry ID
- NCT06753981
- Conditions
- Arterial Pulmonary Hypertension (PAH)
- Interventions
- Endothelin receptor antagonist (ERA) combined with PDE5i/sGC agonist dual therapy prostacyclin drugs
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Recruiting
- Start
- 2024-12-10
- Completion
- 2027-02-14
- Enrolment
- 48
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionArterial Pulmonary Hypertension (PAH)InterventionEndothelin receptor antagonist (ERA) combined with PDE5i/sGC agonist dual therapy prostacyclin drugsPhaseNot recordedRegistry statusRecruitingPulmonary Hypertension: Intensification and Personalisation of Combination Rx
NCT05825417 · start 2023-06-14
Registered record
- Registry ID
- NCT05825417
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Selexipag; Riociguat; CardioMEMS pulmonary artery pressure monitor; Confirm Rx; Sotatercept
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Active not recruiting
- Start
- 2023-06-14
- Completion
- 2028-01
- Enrolment
- 70
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPulmonary Arterial HypertensionInterventionSelexipag; Riociguat; CardioMEMS pulmonary artery pressure monitor; Confirm Rx +1 morePhasePhase 4Registry statusActive not recruitingA Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option
NCT05179876 · start 2022-05-04
Registered record
- Registry ID
- NCT05179876
- Conditions
- Hypertension, Pulmonary
- Interventions
- Macitentan; Selexipag; Macitentan/Tadalafil FDC
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Recruiting
- Start
- 2022-05-04
- Completion
- 2030-09-30
- Enrolment
- 280
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypertension, PulmonaryInterventionMacitentan; Selexipag; Macitentan/Tadalafil FDCPhasePhase 3Registry statusRecruitingA Study of Selexipag Assessing Right Ventricular Remodeling in Pulmonary Arterial Hypertension by Cardiac Magnetic Resonance Imaging
NCT04435782 · start 2021-07-07
Registered record
- Registry ID
- NCT04435782
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- JNJ-67896049
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Terminated
- Start
- 2021-07-07
- Completion
- 2023-07-28
- Enrolment
- 9
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPulmonary Arterial HypertensionInterventionJNJ-67896049PhasePhase 4Registry statusTerminatedRWD Patients With Pulmonary Arterial Hypertension Treated With IP Prostacyclin Receptor Agonists
NCT05600218 · start 2021-06-01
Registered record
- Registry ID
- NCT05600218
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- No intervention - Observational study
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Unknown
- Start
- 2021-06-01
- Completion
- 2024-12-31
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPulmonary Arterial HypertensionInterventionNo intervention - Observational studyPhaseNot recordedRegistry statusUnknownA Study of Selexipag in Participants Who Participated in a Previous Selexipag Study
NCT04565990 · start 2021-05-03
Registered record
- Registry ID
- NCT04565990
- Conditions
- Hypertension, Pulmonary
- Interventions
- Selexipag
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2021-05-03
- Completion
- 2023-11-10
- Enrolment
- 43
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypertension, PulmonaryInterventionSelexipagPhasePhase 3Registry statusCompletedA Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag
NCT03942211 · start 2021-02-26
Registered record
- Registry ID
- NCT03942211
- Conditions
- Sarcoidosis-associated Pulmonary Hypertension
- Interventions
- Selexipag; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Terminated
- Start
- 2021-02-26
- Completion
- 2023-04-19
- Enrolment
- 10
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSarcoidosis-associated Pulmonary HypertensionInterventionSelexipag; PlaceboPhasePhase 2Registry statusTerminatedSelexipag for the Treatment of Schistosomiasis-Associated Pulmonary Arterial Hypertension
NCT04589390 · start 2020-10-15
Registered record
- Registry ID
- NCT04589390
- Conditions
- Pulmonary Hypertension; Schistosomiasis
- Interventions
- Selexipag
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Unknown
- Start
- 2020-10-15
- Completion
- 2022-03-31
- Enrolment
- 20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPulmonary Hypertension; SchistosomiasisInterventionSelexipagPhasePhase 2Registry statusUnknown